Among the emerging molecular drivers of aggressive prostate cancer, human epidermal growth factor receptor 2 (HER2) has gained increasing attention for its established roles in tumorigenesis, metastasis, and treatment resistance, as evidenced in cancers such as breast and gastric malignancies (4–6). The gene discussed is ERBB2; the disease is cancer.